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Abstract
Background: Liver disease is rare in the course of mixed connective tissue disease. Most commonly liver steatosis
or elevated liver function tests are reported and only a few cases of mixed connective tissue disease associated
with autoimmune hepatitis were described.
Case presentation: We report a case of an 11-year old boy with hepatitis on admission to the hospital and
symptoms and signs of mixed connective tissue disease. Autoimmune hepatitis has been confirmed by liver biopsy.
Conclusion: To the best of our knowledge this is the youngest patient with autoimmune hepatitis as a presenting
manifestation of mixed connective tissue disease.
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Background
Mixed connective tissue disease (MCTD) is a systemic
rheumatic disease with overlapping selected clinical fea-
tures of systemic lupus erythematosus (SLE), systemic
sclerosis (SS), polymiositis/dermatomyositis and rheuma-
toid arthritis (RA). High titers of distinct autoantibodies
called anti-U1 ribonucleoprotein antibodies (anti-U1
RNP) are characteristic for MCTD. The most common
presenting manifestations are polyarthritis, Raynaud’s
phenomenon, swollen fingers or hands, myositis, esopha-
geal dysfunction and nonspecific symptoms such as fever,
fatigue, arthralgia or myalgia. During the course of the dis-
ease pulmonary, renal, cardiac, gastrointestinal and central
nervous system manifestations can evolve [1]. Pulmonary
involvement is a common complication but is not usually
clinically evident early in the course of the disease. In re-
cent years, a growing interest has been focused on severe
organ involvement such as interstitial lung disease (ILD)
and pulmonary arterial hypertension (PAH) which can
evolve during the long-term follow-up and can signifi-
cantly influence disease prognosis [2].
MCTD is a rare disease in children. Only about 23 %
of all MCTD cases appear in childhood. Four different
sets of classification criteria for MCTD were developed
and none have been evaluated for children. Kasukawa
criteria are widely used in pediatric population and
require a positive Raynaud’s phenomenon or swollen
hands or fingers, a positive test for anti-U1 RNP and at
least one sign from two out of three disease categories
including SLE, SS or polymyositis. Median age of onset
is 11 years. It is more prevalent in female patients with
female versus male ratio 6:1 [3].
Autoimmune hepatitis is an immune mediated inflam-
mation of the liver of unknown cause. The disease leads
to progressive inflammatory and fibrotic process in the
liver [4, 5]. The condition is chronic and characterized
by interface hepatitis, hypergammaglobulinaemia and
liver-specific serum autoantibodies. The usual age of
presentation for type 1 autoimmune hepatitis is from 10
to 20 years or from 45 to 70 years. It is more common
in women. Approximately 40 % of patients have concur-
rent extrahepatic immunological disease [6].
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Case presentation
An 11 year old boy was admitted to our department in
January 2012 because of polyarthritis, hepatopathy and
Raynaud syndrome. The symptoms first appeared one
year before admission when parents noted white fingers
on both hands. In September 2011, eight months after
the first symptom, the main complaint was fatigue and
loss of appetite. He was not gaining weight. No signifi-
cant fevers above 38 °C were noted, but he was occa-
sionally having mild temperature from 37–38 °C.
Gradually his fingers became blue when he was in a cold
environment. The change of color became fixed in time
and other manifestations developed including headache
and joint pain in fingers, wrists, arms, neck, knees and
ankles. The worst pain was in fingers in the morning
and gradually improved during the day.
Family and his past medical history were unremark-
able. At the time of diagnosis he was not receiving medi-
cations nor herbal or other products.
On admission he appeared tired and pale. Delayed ca-
pillary refill was found, his fingers were livid and cold.
Dermatoscopy showed distorted and widened nail fold
capillaries. He had swellings of proximal interphalangeal
and metacarpophalangeal joints of both hands and swol-
len knees and ankles. Limited range of motion was
found in fingers and thoracolumbar spine. He was not
able to touch the ground with fingers. When he bent the
distance from his fingertips to the floor was 15 cm. On
palpation pain was also induced by performing pressure
on patella on both legs and in elbows.
Laboratory investigations showed elevated erythro-
cyte sedimentation rate, elevated liver function tests,
elevated muscle enzymes, elevated lactate dehydrogen-
ase and elevated serum immunoglobulin G, blood cell
counts were normal (Table 1). Pancreatic enzymes
were also normal. Investigations for metabolic liver
diseases and celiac disease were normal. Serological
markers for viral etiology of hepatitis were negative
(hepatitis A, B and C, Epstein-Barr virus and cyto-
megalovirus). He was previously vaccinated against
Hepatitis B and had positive antibodies against hepatitis B
surface antigen.
He was evaluated for kidney disease. Urine was nor-
mal, protein/creatinine ratio was 7 (normal upper limit
is 20). Serum urea and creatinine level and kidney ultra-
sound were normal.
Immunoserologic tests were positive for antinuclear
antigen antibodies (ANA) titer 1:640 and anti-U1 RNP
antibodies with a titer 1:256. Liver specific antibodies,
anti-ds DNA, antiphospholipid antibodies (anticardioli-
pin, antiβ 2 glycoprotein) were negative, lupus anti-
coagulant was not present. Anti-neutrophil cytoplasmic
antibodies (ANCA) were also negative. Complement ac-
tivation was normal.
Muscle function testing including Kendall test and
Childhood myositis assessment scale testing, were normal.
On skeletal X-ray osteopenia was seen in both hands.
Ultrasound of hips showed effusion in his left hip.
Pulmonary function test showed decreased carbon
monoxide diffusion capacity of the lungs (DLCO) to
56 % of normal value. Lung CT was normal and there
were no signs of ILD.
Abdominal ultrasound showed mild hepatomegaly.
Liver biopsy and endoscopic examinations were per-
formed. Gastroscopy revealed Helicobacter pylori infec-
tion and he received eradication therapy. Colonoscopy
did not show any inflammatory changes.
Liver biopsy revealed a preserved normal architecture.
The majority of the portal tracts were slightly expanded
and contained mild inflammatory cell infiltrate com-
posed of lymphocytes and plasma cells, extending focally
into the liver parenchyma (Fig. 1). Lobular activity was
mild and was composed mainly of lymphocytes at the
sites of hepatocyte drop-out (Fig. 2). An increased num-
ber of apoptotic hepatocytes were also noted. The histo-
logical features were consistent with mild autoimmune
hepatitis.
Based on the clinical signs and laboratory results our
patient fulfilled the Kasukawa diagnostic criteria for
MCTD including Raynaud’s syndrome, polyarthritis, re-
duced DLCO, elevated serum levels of muscle enzymes
and positive anti-U1 RNP antibodies. Elevated liver
enzymes, positive ANA, high titers of serum immuno-
globulin G and negative serology for viral hepatitis
Table 1 Laboratory results before and after treatment. Normal
values are presented in legend
Before treatment 1 month after treatment
ESR (mm/hr) 46 4
E (1012/L) 4.41 4.65
Hb (g/L) 115 131
L (109/L) 4.3 11.8
Pl (109/L) 346 306
AST (μkat/L) 2.57 0.78
ALT (μkat/L) 2.38 1.26
gamma GT (μkat/L) 0.41 0.44
CK (μkat/L) 10.10 4.7
LDH(μkat/L) 5.61 4.85
Aldolase (μkat/L) 283 233
IgG (g/L) 27.1 11.9
Legend: ESR- erythrocyte sedimentation rate (N < 20), E- erythrocyte
(N 4.03–5.29), Hb- Hemoglobin (N 110–145), L- Leukocyte (N 3.8–9.8), Pl- Platelets
(N 175–332), AST- aspartate aminotransferase (N < 0.69), ALT- alanine
aminotransferase (N < 0.52), gamma GT- gamma glutamyltranspeptidase
(N < 0.37), CK- creatine kinase (N < 1.86), LDH- lactate dehydrogenase
(N 2.00–5.43), Aldolase (N <126), IgG- Immunoglobuline G (N 6.36–17.01 g/L)
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indicated a diagnosis of autoimmune hepatitis, which
was confirmed by liver biopsy. On revised scoring sys-
tem for autoimmune hepatitis he scored 16 [7].
The patient was treated with three daily pulses of
intravenous methylprednisolone 15 mg/kg BW followed
by oral glucocorticosteroid which was slowly tapered.
Mycophenolate mofetil and chloroquine were also
started. Significant clinical and laboratory improvements
were achieved in one month (Table 1). The score on re-
vised scoring system for autoimmune hepatitis fell to 11.
Two months after the treatment was started his lung
function tests were better but DLCO decreased from
56 % to 49 %. No symptoms or signs of pulmonary dis-
ease were present. Heart ultrasound was normal. Six
months after treatment was started his DLCO was 69 %
and it remained stable during follow up.
Three years after starting therapy he is in remission
on methylprednisolone 2 mg once per day, mycophe-
nolate mofetil 750 mg BID and hydroxychloroquine
200 mg per day. He is also taking vitamin D3, cal-
cium and pantoprazole. At the last visit his laboratory
results were normal including low level of brain natri-
uretic peptide (BNP), heart US was normal and lung
function tests stable.
The patient and his parents agree with the publication
of the case and publication of liver biopsy pictures. Par-
ents signed informed consent.
Discussion
We presented a case of an 11 year old boy with MCTD
and autoimmune hepatitis confirmed by liver biopsy at
presentation of the disease. This association is exceed-
ingly rare and to the best of our knowledge only one
case of a child with MTCD and autoimmune hepatitis
has been previously described [8]. Our patient was suc-
cessfully treated with methylprednisolone, mycopheno-
late mofetil and chloroquine. His disease remained
inactive on therapy with mycophenolate mofetil and
chloroquine when steroids were tapered to low dose.
Revised scoring system for autoimmune hepatitis fell
from 16 to 11 after treatment was introduced.
Different autoimmune diseases can develop in a single
patient. Analysis of 278 patients with autoimmune hepa-
titis revealed that 40 % of patients were diagnosed with
additional autoimmune diseases [6]. The spectrum of
hepatic manifestations accompanying rheumatic diseases
is also wide and includes chronic active hepatitis, pri-
mary biliary cirrhosis, primary sclerosing cholangitis and
nodular regenerative hyperplasia [9].
In patients with systemic rheumatic diseases liver can
be affected by coexisting autoimmune liver disease like
autoimmune hepatitis or primary biliary cirrhosis by dir-
ect involvement of the liver parenchyma. Liver damage
can also be a consequence of drug toxicity or reactiva-
tion of viral hepatitis because of immunosupressive
treatment [10].
In the course of autoimmune rheumatic diseases ele-
vation of liver functional tests should prompt further
investigations to reveal the reason for liver damage.
Hepatic steatosis, nodular regenerative hyperplasia,
portal vein obliteration, portal hypertension, features
of primary biliary cirrhosis, vascular disorders, granu-
lomatous reactions and rarely portal fibrosis can be
found [11]. Liver biopsy is needed to explain the
etiology of liver damage.
Only a few cases of female adult patients with mixed
connective tissue disease who developed autoimmune
hepatitis were previously described [12–15]. A 40-year
old woman who was diagnosed with an overlap syn-
drome of mixed connective tissue disease and Sjoegren’s
Fig. 1 Inflammatory cell infiltrate consisting of lymphocytes and
plasma cells is seen extending from the portal tract into the liver
parenchyma – mild interface hepatitis. Hematoxylin and eosin,
magnification 400x)
Fig. 2 Mild lobular activity and a Councilman body are clearly
apparent. Hematoxylin and eosin, magnification 400x)
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syndrome was admitted to the hospital with severe cho-
lestatic autoimmune hepatitis and acute liver failure. She
responded well to steroid therapy [12]. Another report
described a case of a 27-year old woman with MCTD as-
sociated with autoimmune hepatitis and thyroiditis [13].
We found only one report of MCTD with autoimmune
hepatitis in children. A 16 year old girl with MCTD de-
veloped autoimmune hepatitis one year after the disease
onset [8].
Long term follow up of a patient with MCTD should
include pulmonary function tests on a regular basis and
imaging if needed. The survival rate of patients with
MCTD depends on lung involvement [2]. An active ILD
was detected in 66 % of MCTD patients [16]. Another
study in patients with MCTD revealed that 52 % of the
patients had abnormal HRCT findings, most commonly
lung fibrosis (35 %) [17]. Mortality in patients with nor-
mal HRCT was 3.3 %, as compared with 20.8 % in
patients with severe lung fibrosis. PAH is another com-
plication of MCTD and has a high mortality rate. Early
diagnosis and treatment of PAH are essential. PAH fre-
quency of 3.4 % was found in a cohort of adult patients
with MCTD [18]. Doppler-echocardiography is used for
diagnostic screening of patients at risk as well as serum
pro-BNP and DLCO. The diagnosis needs to be con-
firmed by right heart catheterization, which is recom-
mended in all patients with suspected PAH [19].
Conclusions
In conclusion, MCTD and autoimmune hepatitis are
both rare diseases in children. To the best of our
knowledge, we presented the first report of a child
with MCTD and autoimmune hepatitis which was
confirmed at the initial presentation. Liver toxicity
due to medications and infections should be excluded
in such cases and liver biopsy is necessary to establish
correct diagnosis.
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